Given the current economic situation, it is necessary for companies and organizations to opt for the economical alternatives for research projects including drug discovery and development.We would like to inspire researchers and scientists to take part in the projects on business-to-business basis.

Aurora is going to take part in the drug discovery project and contributes to preclinical phase research while doing some of the following: providing compounds in any format (10umol, 1mg, 5mg, powder, in DMSO, vials, plates) for free, synthesis and providing of hits and leads also for free.

Aurora's drug repositioning program contains a database of 18,000 drugs registered in the USA, in Europe, in Japan and other countries/parts of the world that allows a quick approval process and speedy commercialization for known drugs having the new or different indications. On the other hand, due the extraordinary large compound collection (11 mln.) almost unlimited source of structures for drug research and development is available. Aurora's approach has proven successful for virus and neurological disorders projects with NIH agencies in the USA.

Aurora's cooperation with NIH agencies based on cutting edge technology for in vitro, in vivo and in some cases clinical study provides a very good quality of hits and leads. Unfortunately a waiting line for tests is huge because Aurora is just one among many sponsors that are involved in numberless NIH projects. A very slow proceeding is a main reason why Aurora is looking for additional providers for in vitro, in vivo and clinical studies. The partners should be able to fulfill the preclinical studies including in vitro and/or in vivo testing.

The obtained results will be available to all consortium partners and shared jointly. We don't think though the projects results should be open source and available as 'generic' molecules. In opposite intellectual property must be protected by jointly owned patents and drafting of legal documents to avoid pitfalls.

The joint venture agreement (or Memorandum of Understanding) should be signed by partners who want to enter into a project together. In the agreement, the details of the deal to set out, what everyone agrees to do and how and when everyone gets paid, what percentage, what timing, taxes etc. A purpose of agreement is to document each party's obligation and to allocate and minimize each party's risks during the performance of drug discovery and drug development. A biological target and disease as well as work plan details should be added to agreement and depend on the discussions and dialogue between the consortium partners.

Please let us know if you are interested in partnership and/or have any questions. Contact details:
Tom Newman
e-mail: aurora@aurorafinechemicals.com
Phone: +1 858 549 4700
Fax: +1 858 549 4701